Biotech · Private company · San Diego, CA, US
Sinopia Biosciences, Inc.
Track this companyFree. Adds Sinopia Biosciences, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards10
- Development and Validation of Data Standards and Computational Methods for Large Scale Metabolomics Data Analysis for Data Driven Drug DiscoveryFiscal year 2026 · $1.5MNIH RePORTER 2R44GM154585-02 · fetched Nov 12, 2026
- Preclinical development of a novel therapeutic for Parkinson's diseaseFiscal year 2026 · $3MNIH RePORTER 2R44NS124398-04A1 · fetched Nov 12, 2026
- Development of a metabolomics enabled AI/ML platform for discovery of new treatments to enhance drug sensitivity in cancerFiscal year 2026 · $114.3KNIH RePORTER 5R43CA295316-02 · fetched Nov 12, 2026
- Development of a metabolomics enabled AI/ML platform for discovery of new treatments to enhance drug sensitivity in cancerFiscal year 2025 · $285.6KNIH RePORTER 1R43CA295316-01A1 · fetched Nov 12, 2026
- Development of neural network models to enable efficient metabolomic characterization of compound libraries for data-driven drug discoveryFiscal year 2025 · $350KNIH RePORTER 1R43GM157800-01A1 · fetched Nov 12, 2026
- Preclinical assessment of a novel compound for treating radiation-induced oral mucositisFiscal year 2025 · $39.7KNIH RePORTER 3R44DE031464-03S1 · fetched Nov 12, 2026
- Preclinical assessment of a novel compound for treating radiation-induced oral mucositisFiscal year 2025 · $849.2KNIH RePORTER 5R44DE031464-03 · fetched Nov 12, 2026
- Development and validation of data standards and computational methods for large scale metabolomics data analysis for data driven drug discoveryFiscal year 2024 · $350KNIH RePORTER 1R43GM154585-01 · fetched Nov 12, 2026
- Preclinical assessment of a novel compound for treating radiation-induced oral mucositisFiscal year 2024 · $1.5MNIH RePORTER 2R44DE031464-02 · fetched Nov 12, 2026
- Preclinical development of a novel therapeutic for Parkinson's diseaseFiscal year 2024 · $1.3MNIH RePORTER 5R44NS124398-03 · fetched Nov 12, 2026